Page 76 - MEGIN Book Of Abstracts - 2023

Indiana, USA; Lilly Centre for Clinical Pharmacology, Singa- submission to regulatory authorities and other publica-
pore; Neuroscience, BioPharmaceuticals R&D, AstraZeneca, tions. Data will be made available via the Dementias
Cambridge, UK; Cardiff University Brain Research Imaging Platform UK Data Portal on completion of initial analy-
Centre, School of Psychology, Cardiff University, Cardiff, UK; ses by the NTAD study group.
Department of Psychiatry, University of Cambridge, Cam-
bridge, UK Keywords: Dementia, NEUROLOGY, NEUROPHYSIOLOGY,
Neurophysiology, Protocols & guidelines, RADIOLOGY &
INTRODUCTION With the pressing need to develop IMAGING
treatments that slow or stop the progression of
Alzheimer's disease, new tools are needed to reduce BMJ open (2022), Vol. 12, No. 12 (36521898) (0 citations)
clinical trial duration and validate new targets for hu-
man therapeutics. Such tools could be derived from
neurophysiological measurements of disease. The neurophysiological effect of NMDA-R
antagonism of frontotemporal lobar degeneration
METHODS AND ANALYSIS The New Therapeutics in is conditional on individual GABA concentration
Alzheimer's Disease study (NTAD) aims to identify a (2022)
biomarker set from magneto/electroencephalography
that is sensitive to disease and progression over 1 year. Perry, Alistair; Hughes, Laura E; Adams, Natalie;
The study will recruit 100 people with amyloid-positive Naessens, Michelle; Murley, Alexander G; Rouse,
mild cognitive impairment or early-stage Alzheimer's Matthew A; Street, Duncan; Jones, P Simon; Cope,
disease and 30 healthy controls aged between 50 and Thomas E; Kocagoncu, Ece; Rowe, James B
85 years. Measurements of the clinical, cognitive and
imaging data (magnetoencephalography, electroen- Department of Clinical Neurosciences and Cambridge
cephalography and MRI) of all participants will be taken University Hospitals NHS Trust, University of Cambridge,
at baseline. These measurements will be repeated after Cambridge, CB2 0QQ, UK. [email protected]; MRC
approximately 1 year on participants with Alzheimer's Cognition and Brain Sciences Unit, University of Cambridge,
disease or mild cognitive impairment, and clinical Cambridge, CB2 7EF, UK
and cognitive assessment of these participants will
be repeated again after approximately 2 years. To as- ABSTRACT There is a pressing need to accelerate
sess reliability of magneto/electroencephalographic therapeutic strategies against the syndromes caused by
changes, a subset of 30 participants with mild cogni- frontotemporal lobar degeneration, including symp-
tive impairment or early-stage Alzheimer's disease will tomatic treatments. One approach is for experimental
also undergo repeat magneto/electroencephalogra- medicine, coupling neurophysiological studies of the
phy 2 weeks after baseline. Baseline and longitudinal mechanisms of disease with pharmacological interven-
changes in neurophysiology are the primary analyses tions aimed at restoring neurochemical deficits. Here
of interest. Additional outputs will include atrophy and we consider the role of glutamatergic deficits and their
cognitive change and estimated numbers needed to potential as targets for treatment. We performed a
treat each arm of simulated clinical trials of a future double-blind placebo-controlled crossover pharmaco-
disease-modifying therapy. magnetoencephalography study in 20 people with
symptomatic frontotemporal lobar degeneration (10
ETHICS AND DATA STATEMENT The study has re- behavioural variant frontotemporal dementia, 10
ceived a favourable opinion from the East of England progressive supranuclear palsy) and 19 healthy age-
Cambridge Central Research Ethics Committee (REC and gender-matched controls. Both magnetoencepha-
reference 18/EE/0042). Results will be disseminated lography sessions recorded a roving auditory oddball
through internal reports, peer-reviewed scientific jour- paradigm: on placebo or following 10 mg memantine,
nals, conference presentations, website publication, an uncompetitive NMDA-receptor antagonist. Ultra-

 ontents  Index 55
C